VaxartVXRT
VXRT logo
Fair Value
US$4
Share price08 Jan
US$0.4987.6% undervalued intrinsic discount
Loading
1Y23.75%
7D-3.88%

Oral Vaccine Platform And Dynavax Partnership Will Transform Long Term Prospects

Analyst High Target compiles bullish analysts opinions to create narratives which represent one standard deviation above the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls

Published
08 Jan 26
Views
101
Not Invested

Fair Value vs Share Price

US$4
vs US$0.4987.6% undervalued intrinsic discount
PastFuture-108m148m2015201820212024202620272029Revenue US$128.2mEarnings US$20.8m
-4.7%
Revenue growth
16.2%
Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Vaxart

  • Fair value estimate changes
  • Narrative and analyst updates
  • Key company announcements

Company analysis

Flawless balance sheet and fair value.

Market capUS$120.5m
PB1.3x
Estimated Growth-74.8%
Dividend YieldN/A
Full analysis

CEO & management

Steven Lo
CEO
4.4yrs
CEO Tenure

A clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform.